

# DANAHER CORP.

ISIN: US2358511028 WKN: 235851102 Asset Class: Stock

|  |  |
|--|--|
| <b>Company</b>   | 2022/07/01 22:03:30                              |
|  | <b>Price</b>                                     |
|  | <b>258.05</b>                                    |
|  | USD  |
| <b>Difference</b>  | <span style="color: green;">▲</span> 1.79%(4.53) |



**Contact Details**

DANAHER CORP.  
 --  
 2200 Pennsylvania Avenue NW  
 20037-1701 Washington

Tel: 1-202-828-0850  
 Fax: 1-202-828-0860  
 Web: <http://www.danaher.com>  
 E-mail: -

## Company Profile

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2021           |                        | 2020           |                        | 2019           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 11,648,000,000 |                        | 13,802,000,000 |                        | 25,596,600,000 |                        |
| <b>Common stock capital</b>           |                | 9,000,000              |                | 9,000,000              |                | 8,400,000              |
| <b>Fixed assets</b>                   | 71,536,000,000 |                        | 62,359,000,000 |                        | 36,485,000,000 |                        |
| <b>Equity capital of a company</b>    |                | 45,177,000,000         |                | 39,777,000,000         |                | 30,281,900,000         |
| <b>Cash and cash equivalents</b>      | 2,586,000,000  |                        | 6,035,000,000  |                        | 19,912,300,000 |                        |
| <b>Accrued liabilities</b>            |                | 1,147,000,000          |                | 1,682,000,000          |                | 1,123,400,000          |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 8,140,000,000          |                | 7,402,000,000          |                | 4,932,100,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 29,867,000,000         |                | 28,982,000,000         |                | 26,867,600,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 5,663,000,000          |                | 5,322,000,000          |                | 3,588,400,000          |
| <b>Total assets</b>                   | 83,184,000,000 | 83,184,000,000         | 76,161,000,000 | 76,161,000,000         | 62,081,600,000 | 62,081,600,000         |

## Balance notes

|                            | 2021    | 2020    | 2019    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 80,000  | 69,000  | 60,000  |
| <b>Equity ratio</b>        | 54.32%  | 52.24%  | 48.80%  |
| <b>Debt-equity ratio</b>   | 84.09%  | 91.42%  | 104.94% |

## Others

|                         | 2021   | 2020   | 2019   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 16.46% | 18.89% | 26.41% |

# DANAHER CORP.

ISIN: US2358511028 WKN: 235851102 Asset Class: Stock

## Income statement

|   | 2021           | 2020           | 2019           |
|---|----------------|----------------|----------------|
| Turnover  | 29,453,000,000 | 22,284,000,000 | 17,911,100,000 |
| Net income  | 6,347,000,000  | 3,646,000,000  | 2,432,300,000  |
| EBIT  | 7,494,527,200  | 4,496,907,800  | 3,135,389,260  |
| Operating income before taxes                                 | 7,598,000,000  | 4,495,000,000  | 3,305,300,000  |
| Cash Flow   | 8,358,000,000  | 6,208,000,000  | 3,951,600,000  |
| Net interest income   | -230,000,000   | -202,000,000   | 30,400,000     |
| Research and development expenses                             | 1,742,000,000  | 1,348,000,000  | 1,126,000,000  |
| Income taxes  | 1,251,000,000  | 849,000,000    | 873,000,000    |
| Result from investments in subsidiaries, associates and other | 0              | 0              | 0              |
| Revenues per employee   | 352,479        | 309,199        | 285,801        |

## Board of Directors

## Members of Management Board

|                             |                                |
|-----------------------------|--------------------------------|
| Steven Rales                | Chairman of Board of Directors |
| Elias Zerhouni              | Member of Board of Directors   |
| Jessica Mega                | Member of Board of Directors   |
| Pardis Sabeti               | Member of Board of Directors   |
| Raymond Stevens             | Member of Board of Directors   |
| A. Sanders                  | Member of Board of Directors   |
| Alan Spoon                  | Member of Board of Directors   |
| John Schwieters             | Member of Board of Directors   |
| Linda Filler                | Member of Board of Directors   |
| Mitchell Rales              | Member of Board of Directors   |
| Teri List-Stoll             | Member of Board of Directors   |
| Walter Lohr                 | Member of Board of Directors   |
| Rainer Blair                | Chairman of Managing Board     |
| Brian W. Ellis              | Member of Executive Committee  |
| Christopher M. Bouda        | Member of Executive Committee  |
| Daniel A. Raskas            | Member of Executive Committee  |
| Georgeann F. Couchara       | Member of Executive Committee  |
| Jennifer L. Honeycutt       | Member of Executive Committee  |
| Joakim Weidemanis           | Member of Executive Committee  |
| Jose-Carlos Gutierrez-Ramos | Member of Executive Committee  |